Definitive Healthcare (NASDAQ:DH) Earns Underweight Rating from Barclays

Definitive Healthcare (NASDAQ:DH)‘s stock had its “underweight” rating reissued by stock analysts at Barclays in a report issued on Monday, Marketbeat Ratings reports. They currently have a $4.00 price target on the stock. Barclays‘s target price points to a potential upside of 2.04% from the stock’s previous close.

A number of other brokerages have also commented on DH. Needham & Company LLC reissued a “hold” rating on shares of Definitive Healthcare in a report on Friday, November 8th. Stephens assumed coverage on Definitive Healthcare in a research note on Friday, December 20th. They issued an “equal weight” rating and a $5.00 target price on the stock. Finally, BTIG Research started coverage on Definitive Healthcare in a research note on Tuesday, September 17th. They set a “buy” rating and a $7.00 price target for the company. Two research analysts have rated the stock with a sell rating, six have issued a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat, Definitive Healthcare has an average rating of “Hold” and a consensus target price of $5.72.

Definitive Healthcare Stock Down 0.3 %

Shares of NASDAQ DH opened at $3.92 on Monday. The company has a current ratio of 2.49, a quick ratio of 2.49 and a debt-to-equity ratio of 0.33. The business has a 50-day moving average of $4.37 and a 200-day moving average of $4.51. The firm has a market capitalization of $452.85 million, a price-to-earnings ratio of -1.26, a PEG ratio of 3.14 and a beta of 1.41. Definitive Healthcare has a 12 month low of $3.19 and a 12 month high of $10.62.

Insider Activity at Definitive Healthcare

In other Definitive Healthcare news, insider William Moschella sold 45,000 shares of the stock in a transaction on Tuesday, December 3rd. The shares were sold at an average price of $4.70, for a total transaction of $211,500.00. Following the completion of the sale, the insider now owns 433,830 shares of the company’s stock, valued at $2,039,001. This represents a 9.40 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 14.84% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Definitive Healthcare

A number of hedge funds have recently modified their holdings of DH. Point72 DIFC Ltd boosted its holdings in shares of Definitive Healthcare by 759.9% during the third quarter. Point72 DIFC Ltd now owns 9,296 shares of the company’s stock worth $42,000 after purchasing an additional 8,215 shares during the period. Intech Investment Management LLC bought a new position in Definitive Healthcare during the 3rd quarter valued at approximately $55,000. Sanctuary Advisors LLC purchased a new stake in Definitive Healthcare in the 2nd quarter worth approximately $85,000. Bleakley Financial Group LLC bought a new stake in shares of Definitive Healthcare in the 3rd quarter worth approximately $74,000. Finally, Glenmede Trust Co. NA increased its stake in shares of Definitive Healthcare by 41.1% during the third quarter. Glenmede Trust Co. NA now owns 18,423 shares of the company’s stock valued at $82,000 after buying an additional 5,362 shares during the period. Hedge funds and other institutional investors own 98.67% of the company’s stock.

About Definitive Healthcare

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.